{"name":"DualityBio Inc.","slug":"dualitybio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BNT327","genericName":"BNT327","slug":"bnt327","indication":"Other","status":"phase_2"},{"name":"DB-1310","genericName":"DB-1310","slug":"db-1310","indication":"Other","status":"phase_1"},{"name":"DB-2304","genericName":"DB-2304","slug":"db-2304","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DB-1303/BNT323","genericName":"DB-1303/BNT323","slug":"db-1303-bnt323","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Lopinavir and Ritonavir Tablets","genericName":"Lopinavir and Ritonavir Tablets","slug":"lopinavir-and-ritonavir-tablets","indication":"HIV-1 infection in combination with other antiretroviral agents","status":"marketed"}]}],"pipeline":[{"name":"BNT327","genericName":"BNT327","slug":"bnt327","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DB-1303/BNT323","genericName":"DB-1303/BNT323","slug":"db-1303-bnt323","phase":"phase_3","mechanism":"DB-1303/BNT323 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"DB-1310","genericName":"DB-1310","slug":"db-1310","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DB-2304","genericName":"DB-2304","slug":"db-2304","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lopinavir and Ritonavir Tablets","genericName":"Lopinavir and Ritonavir Tablets","slug":"lopinavir-and-ritonavir-tablets","phase":"marketed","mechanism":"Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.","indications":["HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-24","type":"pipeline","source":"The Manila Times","summary":"DualityBio (9606.HK) Announces 2025 Annual Results - The Manila Times","headline":"DualityBio (9606.HK) Announces 2025 Annual Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNc1lsTmVGYmFzSGkzRXlVX2RMeDI2UlQ0VVJBVkhYMkQ1VlpaMFNCX3gtdzBwZEU5UWtUbWNPWmxhMm5jQ3AyMWtMMXhkVW9RSlM2bTNzVy1SdUt6Vmp0Wjk3T0tvUGZHQktEc1B0aTBBbUNfelU4XzFoOHZWVEdrVFpNYklZbFZNQWFDUlFhbVFaaDdYVE03VlNvdk9VczhYY2Q2Ul9KX0F3c3RKQk1QZVQxa3BuOEJOMnQ2Q1lwc3hLYkc5UEtSWm1wTVNHMVpaQ2Y1SmQ3dGljYS1aWjNIWVotRUI1T1lTLUZMb3ROenV5T2ZPOVl5cnVBV19CbTNabnRhOGQzSXhhY1pDWnBXOGFabw?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"HER2 Positive Gastric Cancer Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQb082MFprbTJ4SmVWOTFMU3RRanhUckhQU1RXZ2xDZnZRUUo4NXBrV1d1N0lwaHp2cllrMXNNcXRVY1hjMU5KRDhLb0xkVjllYVcxZFl2eFByM01jS3cxZ2lPWjVFRVYwREVIYWZLLXE5anRUaUNUV1dVTlQxZlh2WGFHYjlrWjRfZmlGV2lzajJqTjRQQjlaUy1BWmNDeWoyX0dKY0xDclB5akYxWmllVHgxblJxa0JSa2Z1RWhPWQ?oc=5","date":"2026-03-06","type":"deal","source":"fiercepharma.com","summary":"Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC - fiercepharma.com","headline":"Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxORG5jRXpMOGk3c3BGZ0c3VldXZ1A0ektseWdkaE81UGNUMGotWjNqZUItajlTdDY5WFdET2xwQ29aWTBuNlk2anJZdFZHdnB6SlFUZmIySnZySXBMbVE0ZE1tb1V4WWMtOUV5Y0g4ZDVMb3hEdXhrbkdKQ0QzajMwQTV1UkVJOXJsTjZWQ0ZDc1hUcXg1MGZ4VklGX1JaWDJWLTVwQWVWOGdLV3ZkRHc?oc=5","date":"2026-03-02","type":"trial","source":"Endpoints News","summary":"Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC - Endpoints News","headline":"Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNN25FSVl1NEZBS3BxWkFtdThvM3dLT25RakQtM1RWdlk4TGxuRWtvR0FIOXdWbGR1RGpWeUlHc0tVSk5RME9nTDUzbkNXY3JEblhuSGppRHRodm05S0s3dVlRcEpqSkloYjcyaE5LNlJNdEo1eU9wMTV6cUlMQTBOOGxTNW12bEh3T21OTTBreC1hNXlFTDlmbU9XSUxCTzlWbGFrSw?oc=5","date":"2025-09-09","type":"pipeline","source":"BioWorld News","summary":"Late-stage win for Biontech, Dualitybio with breast cancer ADC - BioWorld News","headline":"Late-stage win for Biontech, Dualitybio with breast cancer ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOQmNFRzYzRElnVVREeTRJVVJxRU9XNFUyc1Z1NVppejh2TTJaY3FVa19MY2d0RmhaOEQwWUJtWWR3ZlRDV1ZvUTY0cUNvY1BRdWZkVkpoZjBfbGpLbk16MEN5OFR3TW55RW5QMUNOZU1nTWdMQWU1MEhtQUtYZTZlWVgtdnp1VnFtX0RHMFR6c0ZKaEV1aU43UGVjM1pZVDkzOERmVDF4Y2VBc2tIMXpJZE1vYS0?oc=5","date":"2025-09-05","type":"trial","source":"The Pharma Letter","summary":"BioNTech and DualityBio’s Phase III trial of ADC candidate meets goals - The Pharma Letter","headline":"BioNTech and DualityBio’s Phase III trial of ADC candidate meets goals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQalZDTGl4Yzk3QjBJWEFUQmdBZFVsVzVjSjhUUXk0bjh3QlJpeVNaTVlaZG9fMmlUYkRaYkNYc3FSMkxtWmQ2N1I5dGJGeUNNTlVBX3hxTXc5ZVZJZUpqTTNlamI2a05xVlJUUnhGY2dVRnM0Yk1xc0tMdkdzMmFYcURwSmpwaXo0RXZtaUljVmpSSzI1aVFfalVNUzIyV3RCeXg0ZFo1VjM0ZnRueFplUzZxeWhlZWFVcnhROHl2MGM1UFE4RDFaYUs5M1FWeEEx?oc=5","date":"2025-07-21","type":"regulatory","source":"PR Newswire","summary":"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation - PR Newswire","headline":"DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5fcFpFaG8yRi1IRTd2ZnpTUTRQUmozdnJZS2FFOVRYVDRKQ25WTWNNYUVDUzNYSnFMdjhVQllEdm1GdnNqUnZLUDY0NHNjX2ZIUHF3?oc=5","date":"2025-04-07","type":"pipeline","source":"FirstWord Pharma","summary":"DualityBio seeks to raise up to $200M in Hong Kong listing amid market upheaval - FirstWord Pharma","headline":"DualityBio seeks to raise up to $200M in Hong Kong listing amid market upheaval","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNTzBOdlp0NTk1YURrVkRsMjFyVF9DRVZRYWYyczJTTUJqTUdBYmRyaE9lWHZKMDVDeC1yejRxS1A1ZGVkWC1XMUljM3l3c1dFSmZIcVVPSUxJTG9SRzh5OEhXVldLaUNnTkE4QzBpVGRhRlJYSGJfbVlmS3F6eFpKcXFpek9vcFdKeDRGbWQxdnFmS3FTeW1KaDlrRFNHTXlGWmIyejF0QUhkbF8wMDFmM21sbw?oc=5","date":"2025-04-07","type":"pipeline","source":"Fierce Biotech","summary":"Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO - Fierce Biotech","headline":"Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE8zRm5PaXV5UGRKcUtBVUltMmVJWHJIZWNua1lxclFMbU9ZRFVBNVZLOVl0WkZiNmZrcmhaQTFxNldvWUY2TjVIVEpsVUZGNk9lN2VOc3FLSHVCcF9EcnpMN29LRzg0aEd4a0k3ZmhlR2FQajJMX1hRR2dyMA?oc=5","date":"2025-01-20","type":"deal","source":"Law.asia","summary":"Fangda Advises Duality Biologics on its collaboration with 3SBio Inc. for commercialization of HER2 ADC in Greater China region - Law.asia","headline":"Fangda Advises Duality Biologics on its collaboration with 3SBio Inc. for commercialization of HER2 ADC in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPX3pOVlpXWmh3eGg3OEhCZjRfQTFqV3hTUmhvMU4xY3YzS3dZZDNWVGNsb1JDMWljYUxfNmdWNjRBNUY2RzRjM0pPQWZfZ0ZCS3NDRjItTzA2MGZFZjJJTHlfb3JfbUgwM2NJa0dGSTQwZU5BcFBGdUdOVHQ0NHFhWkJnQzYzYy1IQWxjVVNSNy1IN1VMbTVoT2dfM3dtQ1dKcGNSa0VVMTRTUDhrcWhPX3ZXdnhsTTJxRUsyc01wbl9odXkwUVI5ZlhxbmZJdl9sTkl6S010ekQ4dmVkNW1LbktLTW1GRDRnSHIybm1qMjZkY1VydnlCVmNyOXpoZUhFOXBLSEVRM0YzS3lzaklXMno3RVE?oc=5","date":"2025-01-07","type":"deal","source":"Business Wire","summary":"Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate - Business Wire","headline":"Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQU0luNlNqM1p3WDVvaU5RZ3J5ZkFYMUZZeTl4bG92TzUwMEg3QWJnRjFCaVdtT3FaTDVFcUJuMVkwcVM0dmZuRmRlREZpRE1kYnFQMy1KU2xkQVhNYkR4cHdwb1g4QmlKY2FsZUpWb2wyTlJ6NGNNcHY2bnB5WnpUeGN3QjBoY0pHTURRVmwyZUVBR3JlTFBjNmZBUlVKaGx1ZVV4cXFQWEtmUQ?oc=5","date":"2024-08-30","type":"pipeline","source":"fiercepharma.com","summary":"Fierce Pharma Asia—Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale - fiercepharma.com","headline":"Fierce Pharma Asia—Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":1,"phase_3":1,"phase_1":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}